BioNexus Gene Lab financials
$1.27−2.31%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2K | $22.8K | $483.8K | $2.5M | $2.3M | $2.1M | $2.5M | $2.6M | $2.0M | $2.4M | $2.3M | $2.6M |
| Gross profit | $13.0K | -$790.00 | -$4.0K | $377.7K | $368.0K | $343.5K | $309.2K | $326.5K | $288.7K | $365.0K | $266.6K | $354.3K |
| Gross margin | 17.0% | −3.5% | −0.8% | 14.8% | 16.3% | 16.1% | 12.3% | 12.4% | 14.6% | 15.3% | 11.7% | 13.9% |
| Operating income | -$403.4K | -$571.4K | -$1.1M | -$810.3K | -$769.8K | -$616.2K | -$1.3M | -$1.7M | -$470.9K | -$280.9K | $283.5K | -$2.7M |
| Net income | -$286.5K | -$543.6K | -$1.0M | -$709.0K | -$616.2K | -$623.3K | -$348.3K | -$1.3M | $199.1K | -$103.8K | $308.5K | -$2.6M |
| Net margin | −376.1% | −2379.7% | −214.2% | −27.9% | −27.3% | −29.2% | −13.8% | −51.1% | 10.1% | −4.4% | 13.6% | −102.2% |
| Diluted EPS | $-0.12 | $-0.23 | $-0.51 | $-0.40 | $-0.34 | $-0.35 | $-0.01 | $-0.75 | $0.11 | $-0.01 | $0.02 | $-1.57 |
| EBITDA | -$375.3K | -$543.1K | -$1.1M | -$781.3K | -$742.0K | -$589.5K | -$1.2M | -$1.7M | -$394.6K | -$260.7K | $313.2K | -$2.7M |
| Operating cash flow | -$422.5K | -$147.7K | $961.1K | -$1.2M | -$737.9K | -$824.1K | $219.2K | -$1.6M | -$672.3K | -$37.2K | -$782.5K | -$899.3K |
| Free cash flow | -$422.7K | -$148.0K | $960.1K | -$1.2M | -$759.4K | -$833.1K | $215.2K | -$1.8M | -$844.7K | -$233.3K | -$808.1K | -$1.3M |
| Diluted shares | 2.4M | 2.4M | 2.0M | 1.8M | 1.8M | 1.8M | 50.0M | 1.8M | 1.8M | 17.7M | 17.8M | 1.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.2M | $1.3M | $2.4M | $1.2M | $814.2K | $1.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $52.6K | $54.4K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.7M | $9.0M | $9.3M | $7.6M | $9.4M | $9.5M |
| Total liabilities | $948.0K | $946.9K | $637.9K | $805.0K | $1.9M | $1.7M |
| Shareholders' equity | $7.8M | $8.1M | $8.6M | $6.8M | $7.5M | $7.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology